AYA.AX stock A$3.56 on ASX 11 Feb 2026: First US Salix revenue supports AI growth outlook

AYA.AX stock closed at A$3.56 on the ASX on 11 Feb 2026, up 4.40% on the day after the company reported initial US Salix revenue. Investors are watching Artrya Limited (AYA.AX) for signs that AI product sales can turn growth into durable revenue. Trading volume finished at 206,036 shares versus an average of 743,497, signalling measured interest. The company remains loss-making with EPS -0.18 and PE -19.33, so the market is pricing growth and execution over current profit metrics.

AYA.AX stock: Price action, volume and immediate drivers

Artrya Limited (AYA.AX) closed A$3.56 on ASX with a daily range of A$3.35–A$3.57. The stock rose 4.40% on the day after a company update showing first US revenue from the Salix coronary plaque module. Volume was 206,036 shares, below the 50-day average of 743,497, which suggests selective buying rather than broad momentum.

The earnings calendar shows an upcoming announcement on 24 Feb 2026. That date is a near-term catalyst risk for traders and longer-term buyers.

AYA.AX stock: Fundamental snapshot and valuation metrics

Market cap is A$394,353,600 with 113,320,000 shares outstanding. Trailing EPS is -0.18, producing a negative PE of -19.33. The 50-day price average is A$4.05 and the 200-day average is A$2.36, indicating a recovery from lower levels earlier in the cycle.

Key balance-sheet figures include a current ratio of 8.27 and cash per share of A$0.11, which point to short-term liquidity cover. However, high price-to-book (PB 16.84) and extreme price-to-sales ratios show the market values Artrya primarily for growth potential rather than current sales.

AYA.AX stock: Technicals and short-term momentum

Technical indicators show strength but some overbought signals. RSI is 70.89, MFI is 82.92, and ADX reads 40.86, indicating a strong trend. Bollinger middle band sits near A$4.20, with a lower band at A$3.23, giving a short-term support area.

Traders should note the average true range of A$0.32, which sets typical daily movement. The 50-day average exceeds the 200-day average, supporting a bullish technical bias, though short-term pullbacks remain possible.

AYA.AX stock: Meyka AI grade and what it means

Meyka AI rates AYA.AX with a score of 63.22/100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade balances Artrya’s strong AI product potential with current losses and valuation mismatches.

Investors should treat the grade as one input. Meyka AI is an AI-powered market analysis platform and this grade is informational only, not personal financial advice.

AYA.AX stock: Forecasts, price targets and model projections

Meyka AI’s forecast model projects a 12-month price of A$7.90 and a quarterly target of A$5.83. At the closing price A$3.56, the one-year projection implies an upside of 121.93%. Forecasts are model-based projections and not guarantees.

We present a conservative near-term target of A$5.83, a base 12-month target of A$7.90, and a three-year scenario price of A$16.06. These levels assume Salix commercial traction in the US and stable execution on regulatory and reimbursement channels.

AYA.AX stock: Risks, sector context and investment considerations

Artrya operates in Healthcare, specifically Medical – Healthcare Information Services. Sector peers trade at much higher profit margins and different multiples, making direct PE comparisons imperfect. Key risks include continued negative EPS, reimbursement delays, and slow hospital adoption cycles.

On the positive side, early US revenue from Salix and a strong current ratio give Artrya time to commercialise. Investors should weigh high volatility against the potential long-term payoff from AI medical imaging adoption.

Final Thoughts

Key takeaways on AYA.AX stock: Artrya closed at A$3.56 on 11 Feb 2026 after first US Salix revenue, a tangible commercial milestone. Financials still show loss-making operations with EPS -0.18 and a negative PE. Technicals indicate short-term strength, but RSI at 70.89 warns of potential pullbacks. Meyka AI’s forecast model projects A$7.90 for the next 12 months, an implied upside of 121.93% versus today’s price. Meyka AI’s B grade reflects balanced upside and execution risk. For ASX investors, use the upcoming 24 Feb 2026 earnings date as a catalyst window. Should Salix scale in the US, the market will likely re-rate AYA.AX stock higher; if commercial uptake stalls, downside risk will grow. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.